Concepedia

Author

Sławomir Jeka

University of BydgoszczORCID

Also Known As

Ramesh Gupta, S Jeka, S. Jeka, Slawomir Jeka, Sławomir Jeka

154

Publications

4.5K

Citations

30

H-Index

30

Concepts

All Affiliations

University of BydgoszczWroclaw Medical UniversityCollegium Medicum in BydgoszczPolish Academy of SciencesLudwik Hirszfeld Institute of Immunology and Experimental Therapy
SJ

About

Sławomir Jeka is an author at University of Bydgoszcz specializing in medicine, rheumatology, and autoimmune disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

176

2

Immunology

6

6

121

3

Orthopaedics

2

2

55

4

Pathology

2

2

43

5

Allergy

1

1

15

Sławomir Jeka

×

30

Publications

789

Citations

18

H-Index

YearCitations

Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy

R. Alten, Cristiano A. F. Zerbini, Sławomir Jeka,

Annals of the Rheumatic Diseases

2009

67

Factors associated with quality of life in systemic sclerosis: a cross-sectional study

Matylda Sierakowska, Halina Doroszkiewicz, Justyna Sierakowska,

Quality of Life Research

2019

51

High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage

Mariusz Korkosz, Jerzy Gąsowski, Piotr Leszczyński,

BMC Musculoskeletal Disorders

2013

47

Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial.

E. Maheu, Mohammed Zaïm, Thierry Appelboom,

PubMed

2011

42

Long‐Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate‐to‐ Severe Systemic Lupus Erythematosus: Results From an Open‐Label Extension Study

Daniel J. Wallace, Kathryn Hobbs, Megan E. B. Clowse,

Arthritis Care & Research

2015

39

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

Piotr Wiland, Sławomir Jeka, Eva Dokoupilová,

BioDrugs

2020

37

Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies

Walter Reinisch, Wayne J.G. Hellstrom, Radboud J. E. M. Dolhain,

Annals of the Rheumatic Diseases

2023

37

Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology

Eugeniusz J. Kucharz, Marcin Stajszczyk, Anna Kotulska-Kucharz,

Reumatologia/Rheumatology

2018

35

Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy

Milena Iwaszko, Jerzy Świerkot, Katarzyna Kolossa,

Clinical & Experimental Immunology

2015

32

Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity

Mariusz Korkosz, Jerzy Gąsowski, Piotr Leszczyński,

Scandinavian Journal of Rheumatology

2013

30

Page 1